{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-23-000117","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2023-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.343383+00:00","generated_at":"2026-06-07T09:38:28.043689+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Myriad Genetics CFO Bryan Riggsbee retires; Scott Leffler named successor effective Jan 29, 2024","bullets":["Riggsbee steps down as CFO by Jan 31, 2024; will serve as strategic advisor through March 31, 2024.","New CFO Scott Leffler appointed effective Jan 29, 2024; previously CFO at Clover Health and Sotera Health.","Leffler receives base salary $550k, target bonus 75%, sign-on bonus $400k, and initial RSU grants totaling $2.5M.","Company reiterates 2023 and 2024 financial guidance previously issued on Nov 6, 2023.","Departure not due to disagreements; separation includes consulting fee $2,713.65/week and continued equity vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-23-000117","json":"https://secwatch.observer/filing/0000899923-23-000117.json","markdown":"https://secwatch.observer/filing/0000899923-23-000117.md","text":"https://secwatch.observer/filing/0000899923-23-000117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000117/0000899923-23-000117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000117/mygn-20231215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:38:28.043689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8223f766bd","claim":"R. Bryan Riggsbee departed as Chief Financial Officer at MYRIAD GENETICS INC.","evidence_excerpt":"On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000117/0000899923-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"98e697b5b7","claim":"Scott J. Leffler was appointed as Chief Financial Officer at MYRIAD GENETICS INC.","evidence_excerpt":"On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992323000117/0000899923-23-000117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}